Aegerion Pharmaceuticals Reports Objectives for 2013 Prior to US Launch of JUXTAPID Capsules

Aegerion Pharmaceuticals

today announced its business objectives for 2013 in conjunction with the 31st Annual J.P. Morgan Healthcare Conference in San Francisco. Marc Beer, President and Chief Executive Officer, will discuss these objectives as part of a live presentation which will be available on Aegerion's website, www.aegerion.com, on Tuesday, January 8 at 2:00 p.m. PST (5:00 p.m. EST). "2012 was a year of significant accomplishments for Aegerion culminating with the FDA approval of JUXTAPID in December," said Marc Beer, Chief Executive Officer of Aegerion. "We expect 2013 to be a transformational year for us as a commercial organization as we work to execute on our launch plan and to deliver medicine to patients with homozygous familial hypercholesterolemia (HoFH) in need of treatment." Mr. Beer continued, "Through our outreach efforts, we continue to identify patients who are potential candidates for therapy and we are well prepared to educate providers about JUXTAPID, and to support patient access. We also plan to make JUXTAPID available on a named patient sale basis in certain